Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3286866 | Clinics and Research in Hepatology and Gastroenterology | 2012 | 5 Pages |
Abstract
Carcinoma of the anal canal is a rare disease accounting for 1-5% of gastrointestinal tract malignancies. However, its incidence is increasing worldwide. Chemoradiation is the standard treatment for most patients with squamous-cell carcinoma of the anal canal and was first described by Nigro et al. Since then, no other effective treatment was developed. Patients with metastatic disease should be considered candidates for clinical trials. New treatment strategies, including molecular target therapies, are warranted in order to improve disease control. Despite the rarity of this disease, it is urgent to improve its treatment by introducing targeted therapy in the arena.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Suilane Oliveira, LuÃs Teixeira, Paulo M. Hoff, Aimery de Gramont, Christophe Tournigand,